AI Lab Cuts Antibody Experiment Timeline from 3 Years to 4 Months

For an industry where a single drug candidate can take a decade to reach market and cost over $100 million, MegaRobo's claim that eight scientists can accomplish in four months what traditionally required 40–50 people and 3–4 years is a bold statement. If validated across other therapeutic areas, this AI-driven approach could dramatically accelerate the entire drug development lifecycle.

Chinese AI-tech company MegaRobo Technologies has unveiled operational results from its Megalaxy Laboratory in Suzhou that could fundamentally alter the economics of pharmaceutical research and manufacturing. At a time when the industry still grapples with the "10 years, $1 billion, 10% success rate" paradigm for new drug development, MegaRobo demonstrated that a team of just eight scientists leveraging autonomous AI agents can complete 56 rounds of antibody experiments in four months — work that would conventionally require 40–50 people and three to four years. The system raised prediction accuracy for critical attributes (stability, expression, toxicity, binding affinity) from 70% to approximately 90%, dramatically reducing the trial-and-error cycles that inflate costs and timelines.

“

The system raised prediction accuracy for critical attributes (stability, expression, toxicity, binding affinity) from 70% to approximately 90%, dramatically reducing the trial-and-error cycles that inflate costs and timelines.

This is not a theoretical proof of concept. The Megalaxy Laboratory integrates AI agents that not only design experiments but also command robotic arms, incubators, and liquid-handling workstations in a closed loop: computer-generated designs are physically tested, results are automatically analyzed, and the AI decides the next experimental iteration without human intervention. The system operates around the clock, compressing a decade of work into a fraction of the time. MegaRobo Founder and CEO Huang Yuqing stated the long-term ambition: "We believe the entire new drug development process could eventually be completed within five years." If this holds true, the cost and speed advantages could democratize access to novel therapies, reshape competitive dynamics in the pharma industry, and compel incumbents to rethink their R&D infrastructure.

Beyond the lab, MegaRobo extended its AI agent platform into pharmaceutical manufacturing. At an unnamed large manufacturer where production yield had plateaued at about 80% of the theoretical maximum — already considered industry-leading — the company deployed real-time sensor fusion with historical production data and used AI models to uncover inefficiencies previously missed by human operators. The result was an increase to 95% yield, slashing annual raw material costs by more than 20 million yuan. Additionally, automation allowed one work team to oversee four production lines instead of one, significantly boosting labor productivity. These manufacturing gains are particularly noteworthy because they apply to existing facilities without major capital expenditure, suggesting a rapid return on investment.